Mobile
Tuesday, March 17, 2026
21.8
C
Bengaluru
Hot topics
Healthcare + Hospitality: India’s Next Big Export
Why Indian hospitals must go beyond treatment to build...
Vivek V. Kamath Appointed CEO at PlasmaGen BioSciences
Picture: Deep Bhandari led session at ACG - MedicinMan...
Customer Acquisition Cost (CAC) & Indian Pharma
Introduction
Customer Acquisition Cost (CAC) is a key metric representing...
72nd Republic Day: What’s the Road Ahead for Indian Pharma?
“We are getting too happy, for too little”: these...
Inspirational Frontline Leadership
The last issue of 2016, with articles from K. Hariram and Vivek Hattangadi and new authors, Dr. Ashwin Bonde and Diksha Fouzdar. Diksha's article is the highlight of this issue - an in-depth look at how to embed compliance in the very DNA of a pharma company.
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Hot topics
Finding the middle ground for Doctor-Stakeholder Relationship
Healthcare systems around the world differ – public, private or a mix of both public and private (like in India). With all the variance in healthcare delivery models, the risks to healthcare professionals remain universal: needle injuries to litigations to episodes of threats/ violence
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Eli Lilly’s Acquisition of Adverum Signals Focus on Gene Therapies to Redefine Eye Care
Eli Lilly’s planned acquisition of Adverum Biotechnologies is a...
Prabhir Jha: Digital is not just another technology, it is a mind-set
DigiStorm 2018 was held on 11 September at the...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Newsletter
Get important news delivered directly to your inbox and stay connected!